The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines

The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines

As the past 2 years have been dominated by COVID-19, the upcoming revision of the EU pharmaceutical legislation could not come at a more critical time.  The pandemic increased the relevance and power of the pharmaceutical industry as a key provider of vaccines and...
Get involved !

Get involved !

Sign up here to receive our updates on European health policy and invitations to our events.

Subscribe now

You have Successfully Subscribed!